Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Erdafitinib, an FGFR3 inhibitor, was approved by the FDA in April 2019 for the treatment of FGFR3+ metastatic urothelial carcinoma patients. Here Arlene Siefker-Radtke, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses what’s next for this agent, including its future in Europe and the THOR trial (NCT03390504).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.